Form 4: Ascendis Pharma Executive Acquires Shares
Insider Transaction Report
Ascendis Pharma A/S reports an acquisition of ordinary shares by its EVP & Chief Financial Officer, Scott Thomas Smith.
Summary
- Scott Thomas Smith, EVP & Chief Financial Officer of Ascendis Pharma A/S, acquired 250 ordinary shares.
- The acquisition occurred on May 29, 2026, at a price of $223.32 per share.
- Following this transaction, Mr. Smith beneficially owns 4,267 ordinary shares directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports a routine insider transaction without providing new financial or strategic information.
Positives
- Executive leadership demonstrates confidence through share acquisition.
- Direct beneficial ownership of shares by a key executive.
Future Outlook
No forward-looking statements or guidance are present in this filing.
Industry Context
StockSavvy.ai notes that insider share purchases, while not always indicative of future stock performance, can signal management's belief in the company's prospects.
Stakeholder Impact
- Shareholders may view the executive's purchase as a positive signal of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 05/29/2026 | Transaction Date for share acquisition |
| 06/01/2026 | Date of Report Signature |
Keywords
Ascendis Pharma, ASND, Form 4, insider trading, share acquisition, executive compensation, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.